HemoCue is a global leader in a field of diagnostics known as near patient, or point-of-care, testing. In 1982, HemoCue AB, based in Ängelholm, Sweden, introduced the first system making accurate hemoglobin testing possible in near-patient settings. Since then, more than 350,000 HemoCue systems have been sold worldwide. The company also sells point-of-care tests for glucose, urine albumin, HbA1c, total and differential white blood cell count. HemoCue subsidiaries, affiliates, franchises, and third-party distributors generate revenue in more than 130 countries world wide. HemoCue was acquired by Radiometer, a Danaher company, in April 2013.
HemoCue® victorious in patent validity fight vs. EKF Diagnostics
PRESS RELEASE 2010-11 HemoCue® microcuvette patent prevails in German court battle against EKF Diagnostics...
First FDA CLIA Waiver for quantitative POC Albumin test
PRESS RELEASE 2008-06 HemoCue® Albumin 201 system is the first quantitative point-of-care test, for screening for, diagnosing and monitoring microalbuminuria...
Page 1 of 4